首页> 外文OA文献 >Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
【2h】

Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus

机译:中国SLE处理和研究组(CSTAR)注册表:中国系统性红斑狼疮患者血小板减少症的临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesTo investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE).MethodsThe study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm3 at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm3. The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated.ResultsOf 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%).ConclusionsThrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.
机译:Objectivesto探讨了血小板(TP)在中国系统性红斑狼疮(SLE)患者中的血小板减少症(TP)的患病率,临床特征和预后。方法是基于中国SLE处理和研究组(CSTAR)登记进行的研究。血小板减少症定义为血小板计数<100,000 / mm 3时的注册。严重的血小板减少症定义为血小板计数<50,000 / mm3。 SLE相关TP的患病率,血小板减少症与人口统计数据,器官参与,实验室发现,疾病活动,损伤和死亡率的关联。2104例SLE,342名患者(16.3%)进行血小板减少症。血小板减少症患者患有血小板减少症患者的神经精神症,血管炎,肌炎,肾炎,粘膜皮炎,肾炎,发热,白细胞缺乏症和低存血血症的患病率(P <0.05)显着高。血小板减少症患者的SLE疾病活动指数(SLEDAI)显着高(P <0.05)。多变量分析显示白细胞减少症(或= 2.644),狼疮性肾炎(或= 1.539),低基因血症(或= 1.497)和升高的斯莱达(或= 1.318)与血小板减少症(P <0.05)相关。持续时间(或= 1.006)是严重血小板减少症的独立危险因素,而抗RRNP(或= 0.208)是严重血小板减少症的独立保护因子(P <0.05)。长疾病持续时间是血小板减少症患者死亡率的独立危险因素(RR = 1.006)。血小板减少症患者的6年生存率明显低于没有血小板减少症的患者(88.2%vs.95.5%)。结论stombocytopenia是SLE的常见表现,与白细胞减少症,肾炎和严重疾病活动有关。严重的血小板减少症倾向于长期且相对较为无活性的SLE。具有SLE相关血小板减少症的患者的长期存活率下降。血小板减少症患者的致病持续时间是一种独立的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号